Halozyme Therapeutics (HALO) Other Operating Expenses (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Other Operating Expenses data on file, last reported at $108.8 million in Q1 2026.

• On a quarterly basis, Other Operating Expenses rose 64.36% year-over-year to $108.8 million in Q1 2026; TTM through Mar 2026 was $681.6 million, a 172.06% increase from a year earlier, with the FY2025 full-year figure at $639.0 million, up 177.27% from the prior year.
• Other Operating Expenses for Q1 2026 stood at $108.8 million, down from $435.7 million in the prior quarter.
• Over the last five years, Other Operating Expenses for HALO reached as high as $435.7 million in Q4 2025 and fell as low as $15.9 million in Q1 2022.
• Historically, Other Operating Expenses has averaged $83.9 million across 5 years, with a median of $66.2 million in 2025.
• Across the five-year window, Other Operating Expenses dropped 15.52% in 2024 and jumped 628.44% in 2025, its largest moves.
• Year by year, Other Operating Expenses stood at $46.7 million in 2022, then soared by 50.11% to $70.1 million in 2023, then dropped by 14.62% to $59.8 million in 2024, then soared by 628.44% to $435.7 million in 2025, then tumbled by 75.04% to $108.8 million in 2026.
• Per Business Quant data, the three most recent Other Operating Expenses figures were $108.8 million in Q1 2026, $435.7 million in Q4 2025, and $73.0 million in Q3 2025.